A phase 2, single-blind, randomized, controlled, multi-center study to evaluate the efficacy and safety of SRM003 (Vascugel) in improving the rate of arteriovenous fistula maturation and use in subjects undergoing surgery for creation of an arteriovenous fistula for hemodialysis access

Trial Profile

A phase 2, single-blind, randomized, controlled, multi-center study to evaluate the efficacy and safety of SRM003 (Vascugel) in improving the rate of arteriovenous fistula maturation and use in subjects undergoing surgery for creation of an arteriovenous fistula for hemodialysis access

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs SRM 003 (Primary)
  • Indications Arteriovenous fistula
  • Focus Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 04 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Sep 2014 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015, as reported by ClinicalTrials.gov
    • 18 Jul 2014 According to a Shire Pharmaceuticals media release, no new patients will be enrolled in this and another phase II trial (700237715), but those currently in the trials will be followed for at least 12 weeks for safety.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top